Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

If nausea immediately after GLP-1 RA dosing is a problem, crackers, apples, mint, or ginger-based beverages might help at 30 minutes after the dose of GLP-1 RA.

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

The researchers found that four of 23 individuals (17.4 percent) in the GLP-1 RA group undergoing EGD alone and none of 46 in the control group had food retention (odds ratio, 21.5).

Before adjustment, for example, the GLP-1 RA group tended to be older (median 74 vs 67) and had more comorbidities like CKD (46.5% vs 33.2%) and coronary artery disease (70.1% vs 58.1%).

TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

Within the subclass of GLP-1 RAs, semaglutide increased the most, from 0.2 to 4.4% from 2018 to 2023. Within one year, tirzepatide, which was approved in 2022, reached 1.3%.

The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9% had at least one GLP-1 RA prescription filled posttransplant.